Q2Pharma
Prevention of Multidrug-resistant Bacterial Infections
Company Overview
Snapshot
Founded in November 2015 by Jacob BenArie, Menachem Shoham, and Yaron Shoham, Q2Pharma operates with 1–10 employees. The company has raised $800,000 across one funding round from two investors. In February 2024, Q2Pharma ceased operations.
Business overview
Q2Pharma specializes in the development of small-molecule drugs designed to combat multi-drug-resistant (MDR) bacteria. The company's core technology involves antivirulent agents, such as its lead compound F19, which inhibit bacterial toxin release, thereby enhancing the immune system's ability to resolve infections and potentiating antibiotic efficacy. Q2Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, focusing on drug discovery and development for global markets.
Strategic signal
Q2Pharma ceased operations in February 2024, indicating a significant strategic shift for the company. This development signals to investors and innovation teams that the company's prior research and development efforts in combating multidrug-resistant bacterial infections have concluded, potentially due to market challenges or internal strategic decisions.
Company Intelligence Q&A
- What is Q2Pharma's primary focus?
- Q2Pharma specializes in developing small-molecule drugs for the prevention and treatment of multidrug-resistant bacterial infections, either as standalone medications or in conjunction with existing antibiotics.
- When was Q2Pharma founded?
- Q2Pharma was founded in November 2015.
- What is the status of Q2Pharma?
- Q2Pharma ceased to operate in February 2024.
- What is Q2Pharma's lead compound?
- Q2Pharma's lead compound, F19, is an antivirulent agent that inhibits bacterial toxin release, allowing the immune system to more effectively resolve infections and potentiating antibiotic efficacy.
- What was a key partnership for Q2Pharma?
- In March 2017, Case Western Reserve University and Q2Pharma partnered to develop antivirulence agents aimed at disarming superbugs, with Q2Pharma exclusively licensing the platform technology from the university.